NASDAQ:XBIO
Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc.'s revenue grew 19.0% in fiscal 2025 to $3.0M while operating margin rose to −95.2%, its highest in 7 years. The diluted share count rose 10.4%.Summary generated from Xenetic Biosciences, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$3.0M
Revenue growth+19.0%
Revenue, 5-yr CAGR+46.8%
Gross marginn/a
Operating margin−95.2%
Net margin−90.1%
ROICn/a
Return on equity−40.0%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+10.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 2 | 3 | 3 | 3 |
| Operating income | −6 | −7 | −5 | −4 | −3 |
| Net income | −6 | −7 | −4 | −4 | −3 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 8-KRegulation FD disclosure
Sep 23, 2026 - 8-KEntry into a material agreement
Sep 16, 2026 - 8-KResults of operations and financial condition
Aug 7, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
May 13, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 10-K/AAmended annual report for the fiscal year ended Dec 31, 2025
Apr 24, 2026 - 8-KDirector or officer change
Apr 24, 2026